These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

953 related items for PubMed ID: 10740093

  • 1. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P, Tremblay L, Féger J, Hirsch EC.
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [Abstract] [Full Text] [Related]

  • 2. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T.
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [Abstract] [Full Text] [Related]

  • 3. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R.
    Biol Psychiatry; 2009 Sep 15; 66(6):603-13. PubMed ID: 19520364
    [Abstract] [Full Text] [Related]

  • 4. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.
    Neurobiol Dis; 2009 Aug 15; 35(2):184-92. PubMed ID: 19118628
    [Abstract] [Full Text] [Related]

  • 5. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N, Martín AB, Mendialdua A, Moratalla R.
    Biol Psychiatry; 2006 Jan 01; 59(1):64-74. PubMed ID: 16139809
    [Abstract] [Full Text] [Related]

  • 6. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
    Guigoni C, Doudnikoff E, Li Q, Bloch B, Bezard E.
    Neurobiol Dis; 2007 May 01; 26(2):452-63. PubMed ID: 17350277
    [Abstract] [Full Text] [Related]

  • 7. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R, Lees AJ.
    J Neurol; 2002 Sep 01; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [Abstract] [Full Text] [Related]

  • 8. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.
    Vinuela A, Hallett PJ, Reske-Nielsen C, Patterson M, Sotnikova TD, Caron MG, Gainetdinov RR, Isacson O.
    Brain; 2008 Dec 01; 131(Pt 12):3361-79. PubMed ID: 18988638
    [Abstract] [Full Text] [Related]

  • 9. [Dyskinesia caused by L-DOPA].
    Derkinderen P, Vidailhet M.
    Rev Neurol (Paris); 2002 Dec 01; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [Abstract] [Full Text] [Related]

  • 10. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
    Morissette M, Samadi P, Hadj Tahar A, Bélanger N, Di Paolo T.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr 16; 34(3):446-54. PubMed ID: 20026151
    [Abstract] [Full Text] [Related]

  • 11. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec 16; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 12. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T, Carta M, Muñoz A, Mattsson B, Winkler C, Kirik D, Björklund A.
    Brain; 2009 Feb 16; 132(Pt 2):319-35. PubMed ID: 19039008
    [Abstract] [Full Text] [Related]

  • 13. Opioids and motor complications in Parkinson's disease.
    Samadi P, Bédard PJ, Rouillard C.
    Trends Pharmacol Sci; 2006 Oct 16; 27(10):512-7. PubMed ID: 16908075
    [Abstract] [Full Text] [Related]

  • 14. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M, Landry E, Lévesque D, Rouillard C.
    Neurobiol Dis; 2005 Nov 16; 20(2):450-60. PubMed ID: 15896973
    [Abstract] [Full Text] [Related]

  • 15. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F, Lilliu H, Le Pen C.
    Rev Neurol (Paris); 2001 May 16; 157(5):507-14. PubMed ID: 11438770
    [Abstract] [Full Text] [Related]

  • 16. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD.
    Mov Disord; 1995 Nov 16; 10(6):731-40. PubMed ID: 8749992
    [Abstract] [Full Text] [Related]

  • 17. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
    Chen L, Togasaki DM, Langston JW, Di Monte DA, Quik M.
    Neuroscience; 2005 Nov 16; 132(2):409-20. PubMed ID: 15802193
    [Abstract] [Full Text] [Related]

  • 18. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
    Huot P, Lévesque M, Morissette M, Calon F, Dridi M, Di Paolo T, Parent A.
    J Chem Neuroanat; 2008 Jan 16; 35(1):77-84. PubMed ID: 17706922
    [Abstract] [Full Text] [Related]

  • 19. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK, Banerji T, Jenner P, Marsden CD.
    Mov Disord; 1998 Mar 16; 13(2):234-41. PubMed ID: 9539335
    [Abstract] [Full Text] [Related]

  • 20. [Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].
    Rascol O, Brefel-Courbon C, Blin O.
    Therapie; 1998 Mar 16; 53(1):43-8. PubMed ID: 9773099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.